Navigation Links
XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors
Date:10/25/2007

>

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

The offering was made only to accredited investors, as such term is defined in accordance with the Securities Act of 1933, as amended. The ordinary shares have not been registered under the Securities Act of 1933, or any state securities laws. Therefore, they may not be offered or sold in the United States absent registration under or exemption from the Securities Act of 1933 and any applicable state securities laws. This announcement is neither an offer to sell nor a solicitation of an offer to buy our ordinary shares or warrants to purchase ordinary shares.

Contact:

Ron Bentsur, Chief Executive Officer

Tel: +1-(845)-267-0707 ext. 225

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future financial performance, the delisting of our ordinary shares from the Official List of the United Kingdom Listing Authority, the clinical and business prospects for our clinical compound Bicifadine, growth and operating strategies and similar matters, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ), ... that address unmet medical needs in women,s health, ... will present at the Cantor Fitzgerald Inaugural Healthcare ... , 4:45 PM EDTLocation: , Le Parker Meridien ... www.juniperpharma.com, under  ,Investor, or  click here ...
(Date:6/30/2015)... WA (PRWEB) , ... June 30, 2015 , ... ... a hydrophilic filter that does not sacrifice selectivity to achieve faster flow rates ... combines extremely fine pores with significant open space to allow easy liquid flow ...
(Date:6/30/2015)... ... June 30, 2015 , ... Matrix Marketing Group, LLC , ... hired Gem Swartz to head up its account management department as vice president of ... and Amanda bring senior account management and delivery expertise to the growing Matrix Marketing ...
(Date:6/30/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... focused on the development of autologous cell therapies, announced ... 1/2 clinical trial of RCT-01, being tested for ... been enrolled and their tissue biopsy sent for ... comprised of non-bulbar dermal sheath (NBDS) cells isolated ...
Breaking Biology Technology:Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2Matrix Marketing Group Expands Client Services Team 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
... of the presenters at Digestive Disease Week, addressing the ... S.C., May 29 Zeus, Inc., a leader in ... invited to present at Digestive Disease Week in Chicago ... Ph.D. and GI Endoscopy Specialist Aubrey Sanders will address ...
... L.P., a subsidiary of Mylan Inc. (Nasdaq: ... market and distribute EMSAM(R) in the U.S. EMSAM, a ... which was approved by the U.S. Food and Drug ... depressive disorder. EMSAM previously was marketed and distributed by ...
... cells that can count and "remember" cellular events, using simple ... a specific order. , Such circuits, which mimic those found ... of times a cell divides, or to study a sequence ... count exposures to different toxins. , The team developed two ...
Cached Biology Technology:Zeus to Present at Digestive Disease Week in Chicago 2Dey L.P. to Market EMSAM(R) Skin Patch for Treatment of Major Depressive Disorder 2MIT, BU engineer cellular circuits that count events 2MIT, BU engineer cellular circuits that count events 3
(Date:6/25/2015)... SALT LAKE CITY , June 25, 2015 /PRNewswire/ ... the first steps toward a healthier, happier life. That,s ... app is designed to do. The cutting-edge, portable health ... and offers real-life solutions to help improve your lifestyle ... Sellers Association awards dinner and gala Wednesday night, USANA,s ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, ... and authentication solutions, today announced enhanced functionality of ... authentication solution.  The enhancements build on the ... the DigitalPersona Altus platform and provide expanded ... In today,s environment of increasing ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... has spent more than four decades conducting botanical and ... acres of land throughout the Northeast in areas such as ... applying his ecological knowledge of the area in publications of ... the Adirondack Research Consortium (ARC) today at the 18th Annual ...
... GARY, Ind. A group of proteins that act ... bacteria use a molecular trick to induce bacteria to ... Medicine have determined. The research could point the way ... that are resistant to antibiotics. The proteins, called ...
... say that a newly discovered "survival protein" protects the brain ... interfering with a particular kind of cell death that,s also ... in the May 22 advance online edition of Nature ... fact that when brain tissue is subjected to a stressful ...
Cached Biology News:Scientist recognized for contributions to the sustainability of the Adirondacks 2Innate immune system proteins attack bacteria by triggering bacterial suicide mechanisms 2What doesn't kill the brain makes it stronger 2What doesn't kill the brain makes it stronger 3
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
SHEEP ANTI HUMAN ESTRONE...
Anti-Goat HRP-DAB Cell & Tissue Staining Kit...
... the materials necessary for the isolation and preparation ... analysis. Kit Components: ... bottle containing 220 mL of buffered ammonium chloride. ... (Catalog No. 5113) One bottle containing 220 mL ...
Biology Products: